Trial Profile
Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Mesothelioma; Peritoneal cancer
- Focus Therapeutic Use
- 10 May 2017 Status changed from active, no longer recruiting to completed.
- 24 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 22 Jun 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.